<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Otto JJ</submitter><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>e2000012</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7674190</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(6)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine.&lt;h4>Experimental design&lt;/h4>Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding.&lt;h4>Results&lt;/h4>Stable-isotope labeled peptides are used in the detect</pubmed_abstract><journal>Proteomics. Clinical applications</journal><pubmed_title>Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.</pubmed_title><pmcid>PMC7674190</pmcid><funding_grant_id>P30CA016042</funding_grant_id><funding_grant_id>P30 CA016042</funding_grant_id><funding_grant_id>U01CA086402</funding_grant_id><funding_grant_id>U01 CA214194</funding_grant_id><funding_grant_id>U01CA214194</funding_grant_id><funding_grant_id>P30CA054174</funding_grant_id><funding_grant_id>P50 CA211015</funding_grant_id><pubmed_authors>Albracht B</pubmed_authors><pubmed_authors>Liss M</pubmed_authors><pubmed_authors>Semmes OJ</pubmed_authors><pubmed_authors>Correll VL</pubmed_authors><pubmed_authors>Otto JJ</pubmed_authors><pubmed_authors>Main BP</pubmed_authors><pubmed_authors>Yang LF</pubmed_authors><pubmed_authors>Kislinger T</pubmed_authors><pubmed_authors>Boutros PC</pubmed_authors><pubmed_authors>Hitefield NL</pubmed_authors><pubmed_authors>Leach RJ</pubmed_authors><pubmed_authors>Johnson-Pais T</pubmed_authors><pubmed_authors>Nyalwidhe JO</pubmed_authors><pubmed_authors>Engstroem HA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination.</name><description>&lt;h4>Purpose&lt;/h4>The rs17632542 single nucleotide polymorphism (SNP) results in lower serum prostate specific antigen (PSA) levels which may further mitigate against its clinical utility as a prostate cancer biomarker. Post-digital rectal exam (post-DRE) urine is a minimally invasive fluid that is currently utilized in prostate cancer diagnosis. To detect and quantitate the variant protein in urine.&lt;h4>Experimental design&lt;/h4>Fifty-three post-DRE urines from rs17632542 genotyped individuals processed and analyzed by liquid chromatography/mass spectrometry (LC-MS) in a double-blinded randomized study. The ability to distinguish between homozygous wild-type, heterozygous, or homozygous variant is examined before unblinding.&lt;h4>Results&lt;/h4>Stable-isotope labeled peptides are used in the detect</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2026-04-30T15:59:59.729Z</modification><creation>2021-02-20T17:42:06Z</creation></dates><accession>S-EPMC7674190</accession><cross_references><pubmed>32614141</pubmed><doi>10.1002/prca.202000012</doi></cross_references></HashMap>